Overview

A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)

Status:
Recruiting

Trial end date:
2022-11-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide treatment with lyophilized S95014 in pediatric patients with ALL who completed the CL2-95014-002 study during the induction phase and who are clinically benefitting from S95014 without major toxicity.

Phase:

Phase 2

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborators:

ADIR, a Servier Group company
Les Laboratoires Servier (L.L.S), Russia